Cellectis SA
CLLS3.005USD
+0.055+1.86%
Horário de mercado （ET）Cotações atrasadas em 15 min
216.64MValor de mercado
PerdaP/L TTM
Mais detalhes de Cellectis SA Empresa
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Informações da empresa
Código da empresaCLLS
Nome da EmpresaCellectis SA
Data de listagemFeb 06, 2007
CEODr. David Sourdive, Ph.D.
Número de funcionários224
Tipo de títulosDepository Receipt
Fim do ano fiscalFeb 06
Endereço8, rue de la Croix Jarry
CidadePARIS
Bolsa de valoresNASDAQ Global Market Consolidated
PaísFrance
Código postal75013
Telefone33181691600
Sitehttps://www.cellectis.com/
Código da empresaCLLS
Data de listagemFeb 06, 2007
CEODr. David Sourdive, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Andre C. Muller
Mr. Andre C. Muller
Director
Director
--
--
Dr. Adrian Kilcoyne, M.D.
Dr. Adrian Kilcoyne, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Ms. Kyung Nam-Wortman
Ms. Kyung Nam-Wortman
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
--
--
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Non-Executive Director
Non-Executive Director
--
--
Dr. Cecile Chartier, Ph.D.
Dr. Cecile Chartier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Andre C. Muller
Mr. Andre C. Muller
Director
Director
--
--
Dr. Adrian Kilcoyne, M.D.
Dr. Adrian Kilcoyne, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Ms. Kyung Nam-Wortman
Ms. Kyung Nam-Wortman
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
France
41.51M
0.00%
Other
0.00
0.00%
USA
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: seg, 26 de mai
Atualizado em: seg, 26 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Long Focus Capital Management LLC
6.53%
B Group, Inc.
4.50%
UBS Asset Management (Switzerland)
3.98%
Pfizer Inc
3.86%
UBS Asset Management (Americas) LLC
2.55%
Other
78.58%
Investidores
Investidores
Proporção
Long Focus Capital Management LLC
6.53%
B Group, Inc.
4.50%
UBS Asset Management (Switzerland)
3.98%
Pfizer Inc
3.86%
UBS Asset Management (Americas) LLC
2.55%
Other
78.58%
Tipos de investidores
Investidores
Proporção
Investment Advisor
14.08%
Hedge Fund
6.68%
Corporation
3.86%
Investment Advisor/Hedge Fund
0.49%
Research Firm
0.18%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
74.66%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
78
18.32M
25.34%
-2.37M
2025Q1
83
18.44M
25.50%
-2.58M
2024Q4
88
17.72M
24.57%
+1.29M
2024Q3
106
16.31M
22.62%
-2.61M
2024Q2
105
14.76M
20.47%
-2.65M
2024Q1
113
14.77M
20.56%
-2.69M
2023Q4
124
14.69M
20.46%
-8.13M
2023Q3
142
13.62M
24.51%
-10.91M
2023Q2
155
16.13M
29.02%
-9.56M
2023Q1
162
17.33M
31.20%
-2.13M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Long Focus Capital Management LLC
4.72M
6.53%
+100.00K
+2.17%
Mar 31, 2025
B Group, Inc.
3.26M
4.5%
+175.00K
+5.68%
Mar 31, 2025
UBS Asset Management (Switzerland)
2.88M
3.98%
+1.44M
+100.00%
Mar 31, 2025
Pfizer Inc
2.79M
3.86%
+2.79M
--
Dec 31, 2023
UBS Asset Management (Americas) LLC
1.85M
2.55%
+1.85M
--
Mar 31, 2025
UBS Asset Management Switzerland AG
1.44M
1.99%
--
--
Jan 31, 2025
Macquarie Investment Management
226.88K
0.31%
--
--
Mar 31, 2025
Bellecapital AG
226.07K
0.31%
--
--
Nov 30, 2024
Baillie Gifford & Co.
139.05K
0.19%
-151.38K
-52.12%
Mar 31, 2025
Millennium Management LLC
103.85K
0.14%
-430.70K
-80.57%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ActivePassive International Equity ETF
0%
Avantis International Equity ETF
0%
ActivePassive International Equity ETF
Proporção0%
Avantis International Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
